NewCo Serapha taking path to NASDAQ via merger with Boundless: Deals Report

A new start-up with rights to a clinical program from China intends to merge with flagging public company Boundless, drawing $230 million from an investor syndicate and using the extrachromosomal DNA-directed therapies developer as a vehicle to go public.

If completed, the deal would effectively bring to a close the story of Boundless Bio Inc. (NASDAQ:BOLD), which drew more than $250 million from venture investors and went public in a $100 million listing in 2024. Its lead clinical program had underperformed expectations and the biotech’s value had dwindled, leaving it with some cash runway; the company said Tuesday another clinical program did not meet criteria for continued investigation...